Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

Condition:   COVID-19 Interventions:   Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine;   Biological: Prototype/XBB.1.5 Bivalent Vaccine (5 µg) Sponsor:   Novavax Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials